Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefotaxime desensitization

G Papakonstantinou1, J R Bogner, F Hofmeister

  • 1III Medizinische Klinik, Klinikum Mannheim, Universität Heidelberg.

The Clinical Investigator
|February 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medium-grade proteinuria is a risk factor for incident markers of chronic kidney disease.

HIV medicine·2020
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

First case of Serratia liquefaciens isolated from urinary tract infection in sows and associated clinicopathological and pathological findings.

Letters in applied microbiology·2019
Same author

Sepsis: a frequent topic in a new Editorial Section in INFECTION.

Infection·2019
Same author

Immittance Data Validation using Fast Fourier Transformation (FFT) Computation - Synthetic and Experimental Examples.

ChemElectroChem·2018
Same author

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Leukemia·2018
Same journal

Are heart rate responses reproducible in the tilt-table test?

The Clinical investigator·1994
Same journal

Cyclosporine A enhances total cell calcium independent of Na-K-ATPase in vascular smooth muscle cells.

The Clinical investigator·1994
Same journal

Volumes and Na+/H+ antiporter activity of lymphocytes in patients with congestive heart failure.

The Clinical investigator·1994
Same journal

Primary aldosteronism: difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands.

The Clinical investigator·1994
Same journal

Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma.

The Clinical investigator·1994
Same journal

Comparison between ethanol sclerotherapy and emptying with injection of saline in treatment of thyroid cysts.

The Clinical investigator·1994
See all related articles

This study details successful cefotaxime desensitization in a patient with severe osteomyelitis and drug hypersensitivity. This approach may benefit patients with severe infections when alternative antibiotics are unsuitable.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Severe lumbar osteomyelitis of unknown bacteriology presented a treatment challenge.
  • The patient exhibited hypersensitivity to cefotaxime, necessitating an alternative therapeutic strategy.
  • Alternative antibiotic options were limited, making cefotaxime desensitization a viable consideration.

Observation:

  • A gradual intravenous cefotaxime (cefotaxime) administration protocol was initiated.
  • The daily dosage was incrementally increased over 13 days, reaching 4 g.
  • The patient was monitored for allergic reactions during and after the desensitization process.

Findings:

  • Successful desensitization to cefotaxime was achieved without any allergic reactions.

Related Experiment Videos

  • The patient tolerated the full therapeutic dose of cefotaxime throughout the observation period.
  • No adverse events were noted during the 4-week follow-up.

    • Implications:

    • Cefotaxime desensitization can be a safe and effective option for patients with severe infections and antibiotic hypersensitivity.
    • This strategy is particularly relevant when the causative pathogen is unknown and alternative treatments are unavailable.
    • Consideration of antibiotic desensitization may expand therapeutic options in complex infectious disease cases.